What is it and what does it include?
This was safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 was titrated to reach the most well tolerated dose in the patients. The study enrolled 14 patients 50 years or older who had a clinical diagnosis of probable Alzheimer's disease.
How can I use this dataset to advance my research?
This dataset is ideal if:
- you’re investigating the effects of a brain penetrant histamine H3 receptor antagonist (in this case, GSK239512) and placebo on episodic memory in patients with mild to moderate AD or other cognitive domains.
Has this dataset helped researchers understand Alzheimer’s and other dementias better?
Of course!
- AD & Pharmacokinetics:
In 2013, researchers demonstrated that GSK239512 displayed a satisfactory level of tolerability in patients with Alzheimer’s disease with evidence for positive effects on attention and memory. The findings suggest that a titration regimen with a starting dose of 5-10μg and a maximum dose of 80μg is likely to be a well-tolerated and potentially efficacious regimen for future clinical trials in patients with Alzheimer’s disease. March 2013 – DOI: 10.2174/1567205011310030003